UNASSIGNED: @entity810 ( @entity810 ) is a well-known complication of @entity900 -based chemotherapy; however, its impact on long-term @entity1 survival is unclear. We sought to determine the incidence and risk factors for development of @entity900 -associated @entity810 and its impact on long-term renal function and @entity1 survival. We identified 233 @entity1 who received 629 cycles of high-dose @entity900 (99  9mg/m2) for treatment of @entity135 between 2005 and 2011. These subjects were reviewed for development of @entity810 . @entity900 nephrotoxicity (CN) was defined as persistent rise in serum @entity1011 , with a concomitant decline in serum @entity1760 and @entity972 , in absence of use of nephrotoxic agents and not reversed with hydration. All @entity1 were hydrated per protocol and none had baseline glomerular filtration rate (GFR) via CKD-EPI<60mL/min/1.73m2. The @entity1 were grouped based on development of @entity810 and were staged for levels of injury, per KDIGO- @entity810 definition. Renal function was assessed via serum @entity1011 and estimated glomerular filtration rate (eGFR) via CKD-EPI at baseline, 6- and 12-months. @entity1 with @entity810 were screened for the absence of nephrotoxic medication use and a temporal decline in serum @entity972 and @entity1760 levels. @entity2357 models were constructed to determine risk factors for @entity900 -associated @entity810 . @entity177 was compared among groups using ANOVA. Kaplan-Maier curves and Cox proportional hazard models were constructed to study its impact on @entity1 survival. Of 233 @entity1 , 158(68%) developed @entity810 ; 77 (49%) developed stage I, 55 (35%) developed stage II, and 26 (16%) developed stage III @entity810 . Their serum @entity972 and @entity1760 levels correlated negatively with level of injury (p<0.05). African American race was a significant risk factor for @entity900 -associated @entity810 , OR 2.8 (95% CI 1.3 to 6.3) and 2.8 (95% CI 1.2 to 6.7) @entity1 with stage III @entity810 had the lowest eGFR value at 12 months (p = 0.05) and long-term @entity1 survival (HR 2.1; p<0.01) than @entity1 with no or lower grades of @entity810 . Most common causes of @entity204 were recurrent @entity5 (44%) or secondary malignancy elsewhere (40%). @entity900 -associated severe @entity810 occurs in 20% of the @entity1 and has a negative impact on long-term renal function and @entity1 survival. @entity970 tube placement may be protective and should be considered in high risk- @entity1 .

Understanding the Risk Factors and Long-Term Consequences of XXXX -Associated @entity810 : An Observational Cohort Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity2357 :: ('MESH:C537770', 'Disease') :: ['Logistic regression'] @entity177 :: ('MESH:D051437', 'Disease') :: ['Twelve-month renal function'] @entity810 :: ('MESH:D058186', 'Disease') :: ['AKI', 'Acute kidney injury'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity970 :: ('CHEBI:46793', 'Chemical') :: ['PEG'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
